Drugs that target angiogenesis have emerged as promising anti-cancer therapeutics and, specifically, the antiangiogenic monoclonal vascular endothelial growth factor-blocking antibody, bevacizumab (Avastin), has been approved for use in patients with recurrent GBM. The gene discussed is VEGFA; the disease is cancer.